Who are Bio-Oss's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bioceramic putty, BioMend without ReproBone, bone substitute, bone substitute i-FactorTM, calcium phosphosilicate putty alloplast graft, Premixed Bioceramic material.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bio-oss.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Bio-Oss — Competitive Intelligence Brief

Bio-Oss (Bio-Oss) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bone graft substitute. Area: Orthopedics/Dentistry.

phase 3 Bone graft substitute Orthopedics/Dentistry Biologic Live · refreshed every 30 min

Target snapshot

Bio-Oss (Bio-Oss) — Mohanad Al-Sabbagh. Bio-Oss is a xenogeneic bone graft material derived from bovine bone that provides a scaffold for bone regeneration and osseointegration.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bio-Oss TARGET	Bio-Oss	Mohanad Al-Sabbagh	phase 3	Bone graft substitute
Bioceramic putty	Bioceramic putty	Mohamed Salah Elwakeel	marketed	Biocompatible ceramic material / bone graft substitute
BioMend without ReproBone	BioMend without ReproBone	University of Sao Paulo	marketed	Bone graft substitute
bone substitute	bone substitute	Al-Azhar University	marketed	Bone graft substitute / Biomaterial
bone substitute i-FactorTM	bone substitute i-FactorTM	Istituto Ortopedico Rizzoli	marketed	Bone graft substitute / Osteoinductive biomaterial	Bone morphogenetic protein signaling pathway
calcium phosphosilicate putty alloplast graft	calcium phosphosilicate putty alloplast graft	University of Louisville	marketed	Bone graft substitute
Premixed Bioceramic material	Premixed Bioceramic material	Ain Shams University	phase 3	Bone graft substitute / Bioceramic material

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bone graft substitute class)

Mohanad Al-Sabbagh · 1 drug in this class
Spine BioPharma, Inc · 1 drug in this class
University of Louisville · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bio-Oss — Competitive Intelligence Brief. https://druglandscape.com/ci/bio-oss. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab